- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jan 31, 2017 P2, N=60, Not yet recruiting, Phase classification: P4 --> P=N/A Initiation date: Sep 2016 --> Feb 2017 | Trial primary completion date: Sep 2018 --> Feb 2019
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), nelitolimod (SD-101) / TriSalus Life Sci, UT MD Anderson Cancer Center
New P2 trial, Combination therapy, PD(L)-1 Biomarker, Metastases: Pembrolizumab +/- SD-101 in Hormone-Na (clinicaltrials.gov) - Jan 3, 2017 P2, N=60, Not yet recruiting,
- |||||||||| Erleada (apalutamide) / J&J
Enrollment open, Trial initiation date: Apalutamide and Leuprolide in Intermediate and High-risk Prostate Cancer (clinicaltrials.gov) - Dec 13, 2016 P2, N=57, Recruiting, Initiation date: Sep 2016 --> Mar 2017 | Trial primary completion date: Sep 2018 --> Mar 2019 Not yet recruiting --> Recruiting | Initiation date: May 2016 --> Oct 2016
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Enrollment closed: A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids (clinicaltrials.gov) - Nov 15, 2016 P3, N=288, Active, not recruiting, Initiation date: Oct 2004 --> Oct 2003 Recruiting --> Active, not recruiting
- |||||||||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Trial completion: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - Nov 3, 2016 P2b, N=305, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- |||||||||| Yervoy (ipilimumab) / Ono Pharma, BMS
Trial primary completion date: Ipilimumab + Androgen Depravation Therapy in Prostate Cancer (clinicaltrials.gov) - Oct 19, 2016 P2, N=48, Active, not recruiting, Trial primary completion date: Apr 2016 --> Apr 2018 Trial primary completion date: Jun 2017 --> Jun 2018
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Trial completion, Enrollment change: Effects of Estrogen Deficiency on Energy Expenditure (clinicaltrials.gov) - Oct 5, 2016 P=N/A, N=6, Completed, Active, not recruiting --> Recruiting Active, not recruiting --> Completed | N=12 --> 6
- |||||||||| progesterone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., estradiol valerate / Generic mfg.
Trial primary completion date: Endometrial Receptivity Profile in Patients With Endometrial Proliferation Defects (clinicaltrials.gov) - Oct 4, 2016 P=N/A, N=20, Enrolling by invitation, Active, not recruiting --> Completed | N=12 --> 6 Trial primary completion date: Dec 2015 --> Dec 2017
- |||||||||| leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., docetaxel / Generic mfg.
Enrollment open, Metastases: oligo-mets: A Study of Definitive Therapy to Treat Prostate Cancer (clinicaltrials.gov) - Oct 3, 2016 P2, N=33, Recruiting, Trial primary completion date: Dec 2015 --> Dec 2017 Not yet recruiting --> Recruiting
- |||||||||| leuprolide acetate for depot suspension / Generic mfg.
Enrollment closed, Trial primary completion date: Effects of Estrogen Deficiency on Energy Expenditure (clinicaltrials.gov) - Jun 18, 2016 P=N/A, N=12, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Oct 2015
- |||||||||| Orgovyx (relugolix) / Intas, Gedeon Richter, Takeda, ASKA Pharma, Sumitomo Pharma, Pfizer
Trial completion: A Phase 2 Study to Evaluate the Safety and Efficacy of TAK-385, Together With a Leuprorelin Observational Cohort, in Participants With Prostate Cancer (clinicaltrials.gov) - Jun 5, 2016 P2, N=133, Completed, Trial primary completion date: Sep 2015 --> Sep 2016 Active, not recruiting --> Completed
- |||||||||| anastrozole/levonorgestrel (BAY 98-7196) / Bayer
Enrollment closed: Bay98-7196, Dose Finding / POC Study (clinicaltrials.gov) - May 27, 2016 P2b, N=318, Active, not recruiting, Initiation date: May 2016 --> Sep 2016 | Trial primary completion date: May 2018 --> Sep 2018 Recruiting --> Active, not recruiting
|